Role of cholesterol in regulating apolipoprotein B secretion by the liver

Journal of Lipid Research

Volumn 37, Issue 3, 1996, Pages 439-447

  Thompson, Gilbert R ^a   Naoumova, Rossitza P ^a   Watts, Gerald F ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

hepatocytes; HepG2 cells; lathosterol; mevalonic acid; microsomal triglyceride transfer protein; stable isotopes; VLDL turnover

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

CHOLESTEROL ESTER STORAGE DISEASE; CHOLESTEROL ESTERIFICATION; CHOLESTEROL SYNTHESIS; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACYL COENZYME A; ANIMALS; APOLIPOPROTEINS B; BILE; CHOLESTEROL; CHOLESTEROL ESTERS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER; MEVALONIC ACID;

EID: 0029924138     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Thompson, G. R. 1994. A Handbook of Hyperlipidaemia, revised edition. Current Science Ltd., London.
2. Gordon, D. A., H. Jamil, D. Sharp, D. Mullaney, Z. Yao, R. E. Gregg, and J. Wetterau. 1994. Secretion of apolipoprotein B-containing lipoproteins from HeLa cells is dependent on expression of the microsomal triglyceride transfer protein and is regulated by lipid availability. Proc. Natl. Acad. Sci. USA. 91: 7628-7632.
3. Goh, E. H., and M. Heimberg. 1977. Effects of free fatty acids on activity of hepatic microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase and on secretion of triglyceride and cholesterol by liver. J. Biol. Chem. 252: 2822-2826.
4. Khan, B., H. G. Wilcox, and M. Heimberg. 1989. Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem. J. 258: 807-816.
5. Khan, B. V., T. V. Fungwe, H. G. Wilcox, and M. Heimberg. 1990. Cholesterol is required for the secretion of the very-low-density lipoprotein: in vivo studies. Biochim. Biophys. Acta. 1044: 297-304.
6. Fungwe, T. V., L. Cagen, H. G. Wilcox, and M. Heimberg. 1992. Regulation of hepatic secretion of very low density lipoprotein by dietary cholesterol. J. Lipid Res. 33: 179-191.
7. Dixon, J. L., S. Furukawa, and H. N. Ginsberg. 1991. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem. 266: 5080-5086.
8. White, A. L., D. L. Graham, J. LeGros, R. J. Pease, and J. Scott. 1992. Oleate-mediated stimulation of apolipoprotein B secretion from rat hepatoma cells. J. Biol. Chem. 267: 15657-15664.
9. Furukawa, S., and T. Hirano. 1993. Rapid stimulation of apolipoprotein B secretion by oleate is not associated with cholesteryl ester biosynthesis in HepG2 cells. Biochim. Biophys. Acta. 1170: 32-37.
10. Wu, X., N. Sakata, E. Lui, and H. N. Ginsberg. 1994. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. J. Biol. Chem. 269: 12375-12382.
11. Cianflone, K. M., Z. Yasruel, M. A. Rodriguez, D. Vas, and A. D. Sniderman. 1990. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J. Lipid Res. 31: 2045-2055.
12. Hahn, S. E., K. Adeli, and D. M. Goldberg. 1995. The fenofibrate-mediated decrease in apoB secretion from HepG2 cells occurs by a post-translational mechanism. Nutr. Metab. Cardiovasc. Dis. 5: 117-127.
13. Kohen-Avramoglu, R., K. Cianflone, and A. D. Sniderman. 1995. The role of neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells. J. Lipid Res. 36: 2513-2528.
14. Dashti, N. 1992. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cell. J. Biol. Chem. 267: 7160-7169.
15. Kosykh, V. A., S. N. Preobrazhensky, I. V. Fuki, O. E. Zaikina, V. P. Tsibulksy, V. S. Repin, and V. N. Smirnov. 1985. Cholesterol can stimulate secretion of apolipoprotein B by cultured human hepatocytes. Biochim. Biophys. Acta. 836: 385-389.
16. Tanaka, M., H. Jingami, H. Otani, M. Cho, Y. Ueda, H. Arai, Y. Nagano, T. Doi, M. Yokode, and T. Kita. 1993. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes. J. Biol. Chem. 268: 12713-12718.
17. Huff, M. W., D. E. Telford, H. R. Barrett, J. T. Bilheimer, and P. J. Gillies. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler. Thromb. 14: 1498-1508.
18. Carr, T. P., R. L. Hamilton, Jr., and L. L. Rudel. 1995. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J. Lipid Res. 36: 25-36.
19. Ginsberg, H. N. 1995. Synthesis and secretion of apolipoprotein B from cultured liver cells. Curr. Opin. Lipidol. 6: 275-280.
20. Sniderman, A. D., and K. Cianflone. 1993. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 13: 629-636.
21. Sharp, D., L. Blinderman, K. A. Combs, B. Kienzle, B. Ricci, K. Wager-Smith, C. M. Gil, C. W. Turck, M-E. Bouma, D. J. Rader, L. P. Aggerbcck, R. E. Gregg, D. A. Gordon, and J. R. Wetterau. 1993. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 365: 65-69.
22. Yao, Z., and R. S. McLeod. 1994. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochim. Biophys. Acta. 1212: 152-166.
23. Sparks, J. D., and C. E. Sparks. 1993. Hormonal regulation of lipoprotein assembly and secretion. Curr. Opin. Lipidol. 4: 177-186.
24. Wetterau, J. R., and R. E. Gregg. 1995. Microsomal triglyceride transfer protein: insights into lipoprotein assembly and abetalipoproteinemia. In Atherosclerosis X. F. P. Woodford, J. Davignon, and A. Sniderman, editors. Elsevier Science B.V., The Netherlands. 40-44.
25. Pfohl, M., R. P. Naoumova, C. Klass, W. Knisei, B. Jakober, T. Risler, and G. R. Thompson. 1994. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35: 1946-1955.
26. Russell-Jones, D. L., G. F. Watts, A. Weissberger, R. Naoumova, J. Myers, G. R. Thompson, and P. H. Sönksen. 1994. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone-deficient patients. Clin. Endocrinol. 41: 345-350.
27. Cummings, M. H., G. F. Watts, C. Pal, M. Umpleby, T. R. Hennessy, R. Naoumova, and P. H. Sönksen. 1995. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study. Clin. Sci. 88: 225-233.
28. Cummings, M. H., G. F. Watts, A. M. Umpleby, T. R. Hennessy, R. Naoumova, B. M. Slavin, G. R. Thompson, and P. H. Sönksen. 1995. Increased hepatic secretion of very-low-density lipoprotein apolipopiotein B-100 in NIDDM. Diabetologia. 38: 959-967.
29. Watts, G. F., R. Naoumova, M. H. Cummings, A. M. Umpleby, B. M. Slavin, P. H. Sönksen, and G. R. Thompson. 1995. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidaemic subjects. Metabolism. 44: 1052-1057.
30. Watts, G. F., M. H. Cummings, M. Umpleby, J. R. Quiney, R. Naoumova, G. R. Thompson, and P. H. Sönksen. 1995. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest. 25: 559-567.
31. Cummings, M. H., and G. F. Watts. 1995. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin. Chem. 41: 111-114.
32. Parker, T. S., D. J. McNamara, C. D. Brown, R. Kolb, E. H. Ahrens, A. W. Alberts, J. Tobert, J. Chen, and P. J. de Schepper. 1984. Plasma mevalonate as a measure of cholesterol synthesis in man. J. Clin. Invest. 74: 795-804.
33. Jones, P. J. H., A. S. Pappu, D. R. Illingworth, and C. A. Leitch. 1992. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur. J. Clin. Invest. 22: 609-613.
34. Yoshida, T., A. Honda, N. Tanaka, Y. Matsuzaki, B. He, T. Osuga, N. Kobayashi, K. Ozawa, and H. Miyazaki. 1993. Simultaneous determination of mevalonate and 7α-hydroxycholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid biosynthesis. J. Chromatogr. 613: 185-193.
35. Pappu, A. S., D. R. Illingworth, and S. Bacon. 1989. Reduction in plasma low density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism. 38: 542-549.
36. Scoppola, A., V. M. G. Maher, G. R. Thompson, N. B. Rendell, and G. W. Taylor. 1991. Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry. J. Lipid Res. 32: 1057-1060.
37. Kempen, H. J. M., J. F. C. Glatz, J. A. Gevers Leuven, H. A. van der Voort, and M. B. Katan. 1988. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J. Lipid Res. 29: 1149-1155.
38. Björkhem, I., T. Miettinen, E. Reihnér, S. Ewert, B. Angelin, and K. Einarsson. 1987. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J. Lipid Res. 28: 1137-1143.
39. Elmberger, P. G., A. Kalén, E. Lund, E. Reihner, M. Eriksson, L. Berglund, B. Angelin, and G. Dallner. 1991. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J. Lipid Res. 32: 935-940.
40. Duane, W. C. 1995. Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. J. Lipid Res. 36: 343-348.
41. Uusitupa, M. I. J., T. A. Miettinen, P. Happonen, T. Ebelling, H. Turtola, E. Voutilainen, and K. Pyorala. 1992. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovas latin alone and with cholestyramine or guar gum. Arterioscler. Thromb. 12: 807-813.
42. Schaefer, J. R., D. J. Rader, and H. B. Brewer, Jr. 1992. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr. Opin. Lipidol. 3: 227-232.
43. Parhofer, K. G., P. H. R. Barrett, D. M. Bier, and G. Schonfeld. 1991. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J. Lipid Res. 32: 1311-1323.
44. Foster, D. M., P. H. R. Barrett, G. Toffolo, W. F. Beltz, and C. Cobelli. 1993. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data (Review). J. Lipid Res. 34: 2193-2205.
45. Naoumova, R. P., M. Pfohl, A. Sussekov, C. Neuwirth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1995. Acute upregulation of cholesterol synthesis by LDL apheresis: evidence for a threshold effect. Circulation. 92 (Suppl): I-103.
46. Lewis, G. F., K. D. Uffelman, L. W. Szeto, and G. Steiner. 1993. The effects of acute hyperinsulinemia on very low density lipoprotein (VLDL) triglyceride and VLDL apolipoprotein (apo) B production in normal weight and obese individuals. Diabetes. 42: 833-842.
47. Cummings, M. H., G. F. Watts, M. Umpleby, T. R. Hennessy, J. R. Quiney, and P. H. Sönksen. 1995. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hyperchotesterolemia: a stable isotope study. Atherosclerosis. 113: 79-89.
48. Fisher, W. R., L. A. Zech, and P. W. Stacpoole. 1994. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm. Arterioscler. Thromb. 14: 501-510.
49. 3H]leucine tracer. J. Lipid Res. 32: 1823-1836.
50. Ginsberg, H. N., N-A. Le, M. P. Short, R. Ramakrtshnan, and R. J. Desnick. 1987. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. J. Clin. Invest. 80: 1692-1697.
51. Maher, V. M. G., P. J. Trainer, A. Scoppola, J. V. Anderson, G. R. Thompson, and G. M. Besser. 1992. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. Q. J. Med. 84: 671-679.
52. Axelson, M., and O. Larsson. 1995. Low density lipoprotein (LDL) cholesterol is converted to 27-hydroxycholesterol in human fibroblasts. J. Biol. Chem. 270: 15102-15110.
53. Warwick, G. L., C. J. Packard, L. Murray, D. Grierson, J. P. Stewart, J. Shepherd, and J. M. Boulton-Jones. 1992. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low density lipoprotein metabolism in the nephrotic syndrome. Clin. Sci. 82: 701-708.
54. Venkatesan, S., P. Cullen, P. Pacy, D. Halliday, and J. Scott. 1993. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler. Thromb. 13: 1110-1118.
55. Cabezas, M. C., T. W. A. de Bruin, H. W. de Valk, C. C. Shoulders, H. Jansen, and D. W. Erkelens. 1993. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92: 160-168.
56. Cianflone, K. 1995. The adipsin-acylation stimulating protein pathway and hyperapobetalipoproteinemia. In Atherosclerosis X. F. P. Woodford, J. Davignon and A. Sniderman, editors. Elsevier Science B.V., The Netherlands. 972-976.
57. Teng, B., A. D. Sniderman, A. K. Soutar, and G. R. Thompson. 1986. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J. Clin. Invest. 77: 663-672.
58. Bocan, T. M. A., E. Ferguson, W. McNally, P. D. Uhlendorf, S. B. Mueller, P. Dehart, D. R. Sliskovic, B. D. Roth, B. R. Krause, and R. S. Newton. 1992. Hepatic and nonhepatic synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta. 1123: 133-144.
59. Nawrocki, J. W., S. R. Weiss, M. H. Davison, D. L. Sprecher, S. L. Schwartz, P-J. Lupien, P. H. Jones, M. E. Haber, and D. M. Black. 1995. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. 15: 678-682.
60. Auerbach, B. J., B. R. Krause, C. L. Bisgaier, and R. S. Newton. 1995. Comparative effects of HMG-CoA reductase inhibitors on apoB production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis. 115: 173-180.
61. Naoumova, R. P., A. D. Marais, J. Mountney, J. C. Firth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1996. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 199: 203-213.
62. Nestel, P. J., W. E. Connor, M. F. Reardon, S. Connor, S. Wong, and R. Boston. 1984. Suppression by diet rich in fish oil of very low density lipoprotein production in man. J. Clin. Invest. 74: 82-89.
63. Huff, M. W., D. E. Telford, and P. H. Barrett. 1992. Dietary fish oil plus lovastatin decreases both VLDL and LDL apoB production in miniature pigs. Arterioscler. Thromb. 12: 902-910.
64. Liscum, L., and N. K. Dahl. 1992. Intracellular cholesterol transport. J. Lipid Res. 33: 1239-1254.